CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Letter Agreement • March 11th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This letter agreement (the “Letter Agreement”) supplements the 2016 Import Agreement. Notwithstanding Section 12.10 of the 2016 Import Agreement, the Parties intend this Letter Agreement, when signed by each Party, to be a binding and enforceable statement of additional terms applicable to the 2016 Import Agreement. Unless otherwise expressly provided in this Letter Agreement, terms with initial capital letters are defined as set forth in the 2016 Import Agreement.
IMPORT AND DISTRIBUTION AGREEMENTImport and Distribution Agreement • March 11th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Import and Distribution Agreement (the “Agreement”) is made effective as of the 1st day of January, 2016 (the “Effective Date”), by and between SciClone Pharmaceuticals International China Holding Ltd., an exempted company incorporated under the laws of Cayman Islands, having its principal place of business at P.O. Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands, British West Indies (“SPIL”) and Sinopharm Holding Lingyun Biopharmaceutical (Shanghai) Co. Limited, a company incorporated under the laws of the People’s Republic of China having its principal place of business at RM 1903, No. 175, East Yan’an Road, Huangpu District, Shanghai (“Importer”). SPIL and Importer are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
